Clinical Trial: NCT05022849
A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants
Status:
COMPLETEDPhase:
Phase 1| Lead Sponsor: | Janssen Research & Development, LLC |
| Information Provided By: | Janssen Research & Development, LLC |
| Last Update Posted: | 2026-04-17 |
Study Overview
Brief Summary
The purpose of this study is to determine recommended Phase 2 dose (RP2D) regimen(s) of JNJ-75229414 in Part 1 (Dose Escalation and to determine safety at the RP2D regimen(s) in Part 2 (Dose Expansion).
Official Title
A Phase 1, Dose Escalation Study of JNJ-75229414, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against KLK2 for Metastatic Castration-Resistant Prostate Cancer
Conditions
Prostatic Neoplasms
Intervention / Treatment
- Drug: JNJ-75229414
- Drug: Bridging Therapy
Other Study ID Numbers
- CR108972
- 75229414MPC1001
Start Date (Actual)
2021-09-28
Primary Completion Date (Actual)
2026-03-11
Study Completion Date (Actual)
2026-03-11
Enrollment (Actual)
15
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | Janssen Research & Development, LLC |
| Information Provided By: | Janssen Research & Development, LLC |
| Last Update Posted: | 2026-04-17 |
Study Overview
Brief Summary
The purpose of this study is to determine recommended Phase 2 dose (RP2D) regimen(s) of JNJ-75229414 in Part 1 (Dose Escalation and to determine safety at the RP2D regimen(s) in Part 2 (Dose Expansion).
Official Title
A Phase 1, Dose Escalation Study of JNJ-75229414, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against KLK2 for Metastatic Castration-Resistant Prostate Cancer
Conditions
Prostatic Neoplasms
Intervention / Treatment
- Drug: JNJ-75229414
- Drug: Bridging Therapy
Other Study ID Numbers
- CR108972
- 75229414MPC1001
Start Date (Actual)
2021-09-28
Primary Completion Date (Actual)
2026-03-11
Study Completion Date (Actual)
2026-03-11
Enrollment (Actual)
15
Study Type
Interventional
Phase
Phase 1